LNTH

LantheusA

Nasdaq / Health Care Equipment & Services

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$102.00

+5.9% vs current

Most likely

Base case

45%

Probability

Target price

$88.00

-8.6% vs current

B-

Bear case

30%

Probability

Target price

$76.00

-21.1% vs current

AI sentiment snapshot

Latest data as of 2026-05-09

AI commentary

This is a T+3 post-earnings monitoring setup, not a clean thesis change. Primary-source support is strong because the May 7, 2026 earnings release and 8-K were confirmed, but delayed analyst revision evidence remains thin. The stock was about $93.06 on 2026-05-09 versus the $91.00 anchor on 2026-05-07, implying only a modest positive reaction despite the reported beat/reaffirm framing. No usable social-context coverage was provided, so confidence stays moderate rather than high.

RankAlpha Sentiment Codex - 2026-05-09

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-30catalystPost-earnings digestion stays mixed after Q1 beat but no raiseMedium impact

Q1 revenue rose 1.2% to $377.3M, GAAP EPS rose to $1.80, but adjusted EPS fell 4.6% to $1.46, PYLARIFY sales declined 6.5%, and full-year 2026 guidance was only reaffirmed rather than raised; the next few weeks are likely about whether investors reward cash generation and diversification or focus on slower core oncology growth [#8-K-2026-05-07].

2026-06-29eventLNTH-2501 FDA decision by June 29 remains a real but not clean upside hookHigh impact

Management said the FDA extended the LNTH-2501 PDUFA date by three months to June 29, 2026 to review manufacturing-related information and said the extension was not tied to efficacy or safety; approval would add another NET imaging asset, but the delay keeps execution risk elevated [#8-K-2026-05-07].

2026-10-01catalystPYLARIFY TruVu launch readiness is the larger 2H26 value unlockHigh impact

Lantheus said FDA approved PYLARIFY TruVu and that a phased geographic launch is planned to begin in Q4 2026, but the conversion still depends on manufacturing-site readiness plus coding, coverage, payment, and customer adoption; that makes it a meaningful but still execution-heavy growth bridge into 2027 [#8-K-2026-05-07].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-09 • Updated nightlySource: Internal modelMethodology